# VISTAGEN THERAPEUTICS, INC. (VTGN) · Edgar & Edgarette company card

> Vistagen Therapeutics (VTGN) grew revenue 161% in FY2026 to $1 million, operating margin -5684% against a -3.8% median for pharmaceutical preparations, equity 73.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1411685 · fiscal year ended 2026-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VTGN) · [JSON](https://www.pops4.com/boards/company/VTGN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | 161.1% |
| Revenue growth per year | 3.4% |
| Operating margin | -5683.7% (prior year -11517.1%) |
| Net margin | -5491.3% |
| Operating cash flow | −$66M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $31M |
| Long-term debt | — |
| Total assets | $49M |
| Total equity | $36M |
| Equity ÷ assets | 73.1% |
| Return on equity | -196.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -34.55 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed restructuring or exit costs in the last 12 months; operating cash flow was negative; operating loss: a margin of -5683.7% in FY2026; revenue is hard to predict: its 80% range is ±28%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $1.3M (FY2026). Experience: revenue up 161.1% on the year, up 3.4% a year over 4 years; operating margin -5683.7%, up from -11517.1%. Soundness: equity 73.1% of assets, return on equity -196.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.7M and $3.0M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -5683.7% against a -3.8% median; growth 161.1% against 13.7%.

Range logged 2026-09-20, receipt 3a10e9e362540bb9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 3, latest 2026-08-05 ([filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/0001628280-26-053304-index.htm))
- Item 2.05 Restructuring or exit costs: 1, latest 2026-10-30 ([filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026068627/0001628280-26-068627-index.htm))
- Item 5.02 Director or officer change: 8, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026065559/0001628280-26-065559-index.htm))

## Recent filings

- 8-K · filed 2026-10-30 · 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026068627/0001628280-26-068627-index.htm)
- 8-K · filed 2026-10-09 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026065559/0001628280-26-065559-index.htm)
- 8-K · filed 2026-09-25 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/0001628280-26-063510-index.htm)
- 8-K · filed 2026-09-24 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026063316/0001628280-26-063316-index.htm)
- 8-K · filed 2026-09-22 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026063046/0001628280-26-063046-index.htm)
- 8-K · filed 2026-09-11 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1411685/000162828026061445/0001628280-26-061445-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001411685.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1411685

## Cite

POPS4, Edgar & Edgarette: VISTAGEN THERAPEUTICS, INC. (VTGN) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/VTGN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.